Anti-Human Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) (Evolocumab) (HEK Cell Expressed) – Fc Muted™

Research-grade Evolocumab biosimilars are used as calibration standards or reference controls in pharmacokinetic (PK) bridging ELISAs to ensure reliable quantification of Evolocumab concentrations in serum by generating standard curves that enable accurate interpretation of assay results.

When applied in a PK bridging ELISA, the process involves:

• Generation of Standard Curves: Research-grade biosimilar Evolocumab is serially diluted to known concentrations, creating a range of standards spanning the anticipated clinical sample concentrations. These standards are included in each ELISA plate.
• Assay Readout Comparison: After incubation and detection steps, the measured optical densities for the standards are plotted to establish a standard (calibration) curve, correlating known biosimilar concentrations to absorbance.
• Quantification of Samples: Test serum samples’ signals are interpolated against this standard curve, translating raw ELISA signals into precise Evolocumab concentrations in the samples.

Why biosimilars are used as standards and controls:

• Research-grade biosimilars are structurally and functionally comparable to the clinical reference product (e.g., Repatha®), making them suitable for consistent, reproducible calibration in non-clinical and pre-clinical research settings.
• Proper validation, using either the reference product or a highly characterized biosimilar, ensures that the ELISA accurately reflects therapeutic drug levels instead of non-specific background.

In-bulk approach (with reference to calibrators and controls):

• Calibrators: Known concentrations of research-grade biosimilar Evolocumab are used to create the analytical curve for quantitation.
• Reference Controls (Quality Controls): These are independently prepared samples with defined (usually low, medium, and high) Evolocumab concentrations verifying assay accuracy, recovery, and precision within every assay run.

ELISA details (for Evolocumab quantification):

• Most ELISAs for monoclonal antibodies—including Evolocumab—are based on the sandwich principle:

  • The assay plate is coated with a capture reagent.
  • Both standards (biosimilar) and serum samples are added to wells.
  • After washing, a labeled detection antibody is added.
  • The assay develops a colorimetric signal proportional to drug concentration.

• The measured absorbances from unknown patient samples are compared against the standard curve, thus yielding the serum concentration of Evolocumab.

In summary, research-grade Evolocumab biosimilars serve as critical assay calibrators and benchmarks in PK bridging ELISA, facilitating reproducible and accurate quantitation of drug concentration in clinical and research samples by providing both the calibration curve and internal quality controls.

The primary models where a research-grade anti-PCSK9 antibody is administered in vivo to study tumor growth inhibition and characterize tumor-infiltrating lymphocytes (TILs) are syngeneic mouse models, most notably the Lewis lung carcinoma (LLC) model in C57BL/6 mice.

Key context and details:

• Model Type: Syngeneic mouse models are preferred for these studies because they maintain an intact, functional murine immune system, enabling analyses of antitumor immunity and TIL responses in an immunocompetent context.

• Tumor Model: The most prominent published research uses the LLC syngeneic model. Tumor cells (LLC cells) are injected subcutaneously into C57BL/6 mice. Treatment commences after tumors are established.

• Antibody Used: A research-grade PCSK9 neutralizing antibody (for preclinical studies, often evolocumab, or research-grade analogs) is administered systemically, either alone or in combination with other agents such as CD137 agonist antibodies.

• Readouts:

  • Tumor Growth Inhibition: Tumor volume is measured over time to determine the efficacy of PCSK9 blockade, alone and with combination therapies.
  • TIL Characterization: Flow cytometry of tumor tissue is performed to quantify immune subsets (e.g., CD8⁺ T cells, granzyme B⁺ CD8⁺ T cells, CD4⁺ T cells, Tregs). PCSK9 inhibition increases intratumoral CD8⁺ T cells and cytotoxic granzyme B⁺ cells, and decreases Tregs.

• Data Summary: In the LLC syngeneic setting:

  • Anti-PCSK9 (with or without CD137 costimulation) delays tumor growth.
  • TIL profiling shows significant expansion of CD8⁺ T cells and granzyme B⁺ CD8⁺ T cells, with reduction of regulatory T cells (Tregs), implicating improved antitumor immunity.

• Humanized Models: The majority of published studies characterizing anti-PCSK9 antibody effects on TILs employ syngeneic—not humanized—models because murine immune elements are required for full TIL evaluation. There is little evidence in the current literature of humanized mouse models (i.e., immunodeficient mice engrafted with human immune cells and human tumors) specifically used for anti-PCSK9 antibody TIL studies. This is likely due to the need for robust, reproducible immune readouts.

Summary Table: Syngeneic vs. Humanized Models for Anti-PCSK9 TIL Studies

Conclusion:
Syngeneic mouse models, especially the LLC model in C57BL/6 mice, are the standard preclinical system for in vivo administration of anti-PCSK9 antibodies to study tumor growth inhibition and characterize TILs. Humanized models have not played a prominent role in published anti-PCSK9/TIL work to date.

Researchers investigate the synergistic effects of Evolocumab (a PCSK9 inhibitor, sometimes studied or developed as biosimilars) with other checkpoint inhibitors (such as anti-CTLA-4 or anti-LAG-3 agents) by combining them in preclinical and, increasingly, early-phase clinical models of immune-oncology. This combinatorial strategy is explored to overcome tumor resistance, enhance immune recognition, and drive superior antitumor responses.

Key points on experimental approaches and rationale:

• Mechanism of synergy: Evolocumab blocks PCSK9, which not only lowers LDL cholesterol but also increases the levels of MHC I proteins on tumor cells, making them more visible to T cells and potentially enhancing the efficacy of checkpoint inhibitors that rely on T cell-mediated anti-tumor activity.

• Preclinical models: Mouse studies have shown that combining Evolocumab with immune checkpoint inhibitors (e.g., anti-PD-1/PD-L1 or anti-CTLA-4 antibodies) slows tumor growth more effectively than either approach alone. This is attributed to improved T cell access and recognition of tumor antigens due to increased MHC I surface expression.

• Multiple checkpoint blockade: Other checkpoint inhibitors (like anti-CTLA-4, anti-LAG-3) target different immune-suppressive pathways. Combining these with PCSK9 inhibition aims to address non-overlapping mechanisms of tumor immune evasion, maximizing T cell activation at multiple points—lymph nodes (CTLA-4), tumor site (PD-1/PD-L1), and additional regulatory axes (LAG-3).

• Clinical studies: While triple-combination strategies (PD-1/PD-L1, CTLA-4, and LAG-3) are actively under investigation, published results so far mainly involve combinations of conventional checkpoint inhibitors. Research directly studying Evolocumab biosimilars in combination with these novel checkpoint inhibitors is ongoing and at an early stage.

• Endpoints and readouts: Studies typically measure tumor growth, survival, immune cell infiltration, MHC I expression, and immune activation markers to assess synergy.

Summary Table: Common Strategies in Complex Immune-Oncology Combinations

Current limitations:

• Most published combination studies involve PCSK9 inhibitors with anti-PD-1/PD-L1 agents, with less preclinical or clinical data reported for combinations with anti-CTLA-4 or anti-LAG-3 specifically.
• The role of PCSK9 inhibition on checkpoint function is an evolving area, and studies with actual biosimilar versions, instead of Evolocumab originator, are less well-documented in the literature to date.

In summary:
Researchers use Evolocumab (or its biosimilars) in combination with diverse checkpoint inhibitors in mouse and emerging clinical models, mainly to test whether upregulating MHC I and reducing immune escape can be synergistically exploited with blockade of multiple immune checkpoints, leading to better outcomes in difficult-to-treat cancers.

A biosimilar of Evolocumab can be used as the capture or detection reagent in a bridging anti-drug antibody (ADA) ELISA to monitor a patient’s immune response against evolocumab by exploiting the ADA’s ability to bind to two identical drug molecules simultaneously.

Context and Mechanism:

• Bridging ADA ELISA Principle:

  • This assay detects bivalent anti-drug antibodies that form a "bridge" between two versions of the drug:
    • One molecule of evolocumab (or its biosimilar) is immobilized on the plate to capture ADA from the patient sample.
    • Another, differently labeled molecule (typically biotinylated, HRP-conjugated, or digoxigenin-labeled) is added for detection, allowing the ADA to bridge both.

• Use of Biosimilar as Reagent:

  • Capture Reagent: The biosimilar can be coated on the ELISA plate, serving as the "bait" to capture any ADA against evolocumab present in the patient’s serum.
  • Detection Reagent: After patient ADA is captured, a labeled form of the evolocumab biosimilar is added; if ADA is present, it will bind both the immobilized and labeled biosimilar, forming a detectable complex.
  • The biosimilar is used because it has structural similarity to the reference drug—ensuring the ADA elicited by the original drug are also detected when using the biosimilar in the assay.

• Why Use a Biosimilar?

  • Manufacturer supply, ethical/clinical considerations, or intellectual property issues may restrict use of the originator molecule.
  • The biosimilar, being analytically and functionally comparable, ensures assay coverage for potential ADA without risk of cross-reactivity from unrelated reagents.

Assay Steps (Typical Protocol):

• Plate is coated with evolocumab biosimilar (usually unlabeled).
• Patient serum is incubated in the well. If ADA are present, they bind the coated biosimilar.
• A detection reagent (the same biosimilar, but labeled) is added. ADA, if bivalent, bridge between coated and labeled molecules.
• Substrate is added; signal (colorimetric/fluorescent) correlates to the ADA concentration.

Technical Considerations:

• Control experiments should verify the biosimilar and reference product exhibit equivalent binding to ADA.
• Bridging assay specificity can be limited by matrix effects or pre-existing antibodies; high-quality reagents and controls are essential.

Summary Table: Evolocumab Biosimilar Roles in Bridging ADA ELISA

This approach is standard in immunogenicity monitoring of monoclonal antibodies, including evolocumab.